Metabolites for NK-I antagonists for emesis

Details for Australian Patent Application No. 2006226665 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Funk, Christoph; Koblet, Andreas; Hoffmann, Torsten

Agent Spruson & Ferguson

Pub. Number AU-B-2006226665 (Modified Examination)

PCT Pub. Number WO2006/099968

Priority 05102359.6 23.03.05 EP

Filing date 14 March 2006

Wipo publication date 28 September 2006

Acceptance publication date 27 January 2011

International Classifications

C07D 213/75 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/44 (2006.01) - Non-condensed pyridines

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

Event Publications

18 October 2007 PCT application entered the National Phase

  PCT publication WO2006/099968 Priority application(s): WO2006/099968

27 January 2011 Application Accepted

  Published as AU-B-2006226665 (Modified Examination)

26 May 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006226669-Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists

2006226649-Chromophore coated metal oxide particles